MYELODYSPLASTIC SYNDROME

This study tests a drug called FT-2102 (olutasidenib) in people with acute myeloid leukemia or myelodysplastic syndrome whose cancers have a specific IDH1 gene mutation. The drug is given alone or combined with standard chemotherapy drugs (azacitidine or cytarabine). The goal is …

This study tested whether removing a specific type of immune cell (naïve T cells) from donor stem cell grafts could prevent graft-versus-host disease (GVHD) after a stem cell transplant for blood cancers. The trial enrolled 84 patients who received high- or medium-intensity chemo…

This study tested a three-drug combination (navitoclax, venetoclax, and decitabine) in 6 adults with high-risk myelodysplastic syndrome (MDS) that came back or didn't respond to standard therapy. The goal was to find the safest dose and see if the combo could shrink or control th…

This study tested a drug called ustekinumab in 8 people with a rare, severe form of Behçet's syndrome affecting the gut, along with a blood disorder called myelodysplastic syndrome. The goal was to see if the drug could control gut symptoms and reduce disease activity over 24 wee…

This phase 1 trial tested two immunotherapy drugs, nivolumab and ipilimumab, in 29 patients whose acute myeloid leukemia or myelodysplastic syndrome came back or did not respond after a donor stem cell transplant. The goal was to find the safest dose and see if the drugs could he…

This study tested different drug combinations to prevent graft-versus-host disease (GVHD) in 174 people with blood cancers receiving stem cells from an unrelated donor. GVHD is a serious side effect where donor cells attack the patient's body. The goal was to find which drug regi…

This study tested a personalized geriatric optimization plan (GO!) in 30 adults aged 60 and older who were getting a donor stem cell transplant for blood cancers or bone marrow failure. The plan included tailored advice on diet, sleep, activity, and medications to improve physica…

This phase II trial tested whether adding the drug itacitinib to standard medications (tacrolimus and sirolimus) can better prevent graft-versus-host disease (GVHD) in 59 patients with blood cancers receiving donor stem cell transplants. GVHD occurs when donor immune cells attack…

This study tested a new method of cord blood transplantation in 13 children and young adults with high-risk myeloid cancers. The approach uses a molecule called UM171 to grow more stem cells from a single cord blood unit, aiming to speed up recovery and reduce complications. Earl…

This phase 2 trial tested a two-step stem cell transplant approach for 47 patients with high-risk blood cancers like leukemia and lymphoma. The method uses the drug cyclophosphamide to lower the chance of graft-versus-host disease (GVHD), a common complication. The goal was to se…

This early-phase trial tested a combination of two drugs, ibrutinib and lenalidomide, in 4 patients with myelodysplastic syndrome (MDS) who had not responded to or could not tolerate standard treatments. The main goal was to find the safest dose and identify side effects. While t…

This early-phase trial tested a cancer vaccine (CDX-1401) along with an immune booster, chemotherapy, and an immunotherapy drug in 8 people with myelodysplastic syndrome (MDS) or low-blast acute myeloid leukemia (AML). The goal was to see if the combination is safe and helps the …

This early-phase trial tested a combination of two chemotherapy drugs, bortezomib (Velcade) and lenalidomide (Revlimid), in 22 adults whose acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) had returned after a stem cell transplant. The main goal was to find the safe…

This early-phase study tested the drug regorafenib in 16 adults with advanced blood cancers like acute myeloid leukemia (AML) that had stopped responding to other treatments. The main goal was to find the safest dose and see how the drug affects cancer-related cell signals. While…

This study tested whether a low dose of the drug cyclophosphamide, given after a stem cell transplant, can prevent graft-versus-host disease (GVHD) — a common and serious complication where donor cells attack the patient's body. The trial involved 35 adults with various blood dis…

This study tested whether adding ready-made natural killer (NK) cells from a donor to a standard stem cell transplant could safely reduce the chance of cancer returning in people with high-risk myeloid cancers like acute myeloid leukemia, myelodysplastic syndrome, and chronic mye…

This study tested whether adding the drug abatacept to standard medications (calcineurin inhibitor and methotrexate) could better prevent severe acute graft-versus-host disease (aGVHD) after a stem cell transplant from an unrelated donor. A total of 186 participants aged 6 and ol…

This study tested a drug called guadecitabine combined with donor lymphocyte infusions in 55 patients whose acute myeloid leukemia or myelodysplastic syndrome came back after a stem cell transplant. The goal was to see if the drug could help the donor immune cells fight the cance…

This study tested a two-step stem cell transplant for people with high-risk blood cancers like leukemia and lymphoma. First, patients got low-dose chemotherapy and radiation to prepare the body. Then, they received donor stem cells and immune cells to help destroy remaining cance…

This study tested whether adding pevonedistat to the standard drug azacitidine helps people with higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, or low-blast acute myeloid leukemia live longer without their disease getting worse. About 454 adults took part…

This phase 1 study tested the drug enasidenib as a maintenance therapy after a stem cell transplant in 23 people with IDH2-mutant acute myeloid leukemia or chronic myelomonocytic leukemia. The goal was to find the safest dose and see how well patients tolerated it. Enasidenib wor…

This study tested whether a combination of two drugs, cyclophosphamide and abatacept, could lower the risk of chronic graft-versus-host disease (GVHD) after a stem cell transplant in people with high-risk blood cancers. GVHD happens when donor cells attack the patient's body. The…

This study tested a drug called abatacept, given as a shot under the skin, to prevent a serious complication called graft-versus-host disease (GVHD) in 29 adults with blood cancers. Participants received a stem cell transplant from a half-matched donor. The goal was to see if aba…

This study looked at 126 people aged 60 and older who had a bone marrow transplant for blood cancers like leukemia or lymphoma. Researchers measured physical abilities, mental health, and stress levels before and after transplant to find traits that help people recover better. Th…

This completed study involved 146 patients with blood cancers who received a stem cell transplant from a donor. Researchers collected blood and tissue samples over a year to study immune cells linked to graft-versus-host disease (GVHD), a common complication where donor cells att…